Back to Authors

Sundt, Wendy J.

Mayo Clinic

Alliance for Clinical Trials in Oncology

Citations 3

“It’s Scary, but I Handle It”: A Qualitative Study on Severe Hypoglycemia Experiences and Reasons for Declining to Participate in a Community Paramedicine Trial to Prevent Hypoglycemia Among People With Diabetes
Huang, Grace L., Tokar, Kathleen, Jacobs, Davi, Krpata, Tami, Sundt, Wendy J., McCoy, Rozalina G. , McCoy, Rozalina Grubina , Golembiewski, Elizabeth H.

Diabetes Obesity and Cardiometabolic CARE | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/doc26-0061 Get It

OBJECTIVE Severe (level 3) hypoglycemia is a life-threatening complication of diabetes associated with substantial risk of recurrence and long-term morbidity. This study examined how adults with diabetes interpreted severe hypoglycemic events and why they declined participation in a community paramedicine program (Diabetes Rescue, Engagement, and Management [Diabetes-REM]) designed to prevent recurrence. RESEARCH DESIGN AND METHODS We conducted semistructured qualitative interviews with adults with type 1 or type 2 diabetes who experienced severe hypoglycemia requiring emergency medical services and declined enrollment in Diabetes-REM. Interviews explored hypoglycemia management experiences and reasons for nonparticipation and were explored using thematic analysis. RESULTS Sixteen adults (44% female; mean age 60 years, range 25–83) participated. Four interrelated themes emerged. First, participants normalized glucose variability as a baseline condition of diabetes and interpreted severe events as situational and correctable when a cause was identifiable, or as inevitable when it was not, rather than as evidence of increased risk. Second, participants relied on prevention systems encompassing habitual routines, caregiver involvement, and glucose-monitoring technologies. Third, severe episodes were frightening and disruptive but typically prompted adjustments to personal management over pursuit of additional clinical support. Finally, reasons for declining Diabetes-REM included time constraints (56%), perceived lack of benefit (25%), and privacy concerns or discomfort with home visits (25%). CONCLUSIONS Among adults who declined a community paramedicine hypoglycemia prevention intervention, severe events were absorbed into existing self-management frameworks rather than viewed as signals of increased risk. Programs targeting hypoglycemia recurrence should account for patients’ risk perceptions and existing management systems, positioning support as complementary rather than corrective.
Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care
Ridgeway, Jennifer L. , Sundt, Wendy J., Krpata, Tami, Glasgow, Amy E. , Smith-Stellflug, Jamie L, Juntunen, Michael B. , Liedl, Chad P., Hentz, Joseph G. , McCoy, Jessica, Sundt, Wendy J S, Krpata, Tami S, Glasgow, Amy, Smith, Olivia A, Lampman, Michelle A. , Menser, Terri L, McCoy, Jessica J, Ridgeway, Jennifer L , Smith, Jamie L , Smith, Olivia A., Menser, Terri , McCoy, Rozalina G.

Journal of Clinical and Translational Science | October 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.646 Get It

Abstract Introduction: Pragmatic trials aim to speed translation to practice by integrating study procedures in routine care settings. This study evaluated implementation outcomes related to clinician and patient recruitment and participation in a trial of community paramedicine (CP) and presents successes and challenges of maintaining pragmatic study features. Methods: Adults in the pre-hospital setting, emergency department (ED), or hospital being considered for referral to the ED/hospital or continued hospitalization for intermediate-level care were randomized 1:1 to CP care or usual care. Referral and enrollment data were tracked administratively, and patient characteristics were abstracted from the electronic health record (EHR). Enrolled patients completed baseline surveys, and a subset of intervention patients were interviewed. All CPs and a sample of clinicians and administrators were invited to complete a survey and interview. Results: Between January 2022 and February 2023, 240 enrolled patients (42% rural) completed surveys, and 22 completed an interview; 63 staff completed surveys and 20 completed an interview. Ninety-three clinicians in 27 departments made at least one referral. Factors related to referrals included program awareness and understanding the CP practice scope. Most patients were enrolled in the hospital, but characteristics were similar to the primary care population and included older and medically complex patients. Challenges to achieving representativeness included limited EHR infrastructure, constraints related to patient consenting, and clinician concerns about patient randomization disrupting preferred care. Conclusion: Future pragmatic trials in busy clinical settings may benefit from regulatory policies and EHR capabilities that allow for real-world study conduct and representative participation. Trial registration: NCT05232799.
Sex differences in NSAID‐induced perturbation of human intestinal barrier function and microbiota
Edogawa, Shoko, Peters, Stéphanie , Jenkins, Gregory D. , Gurunathan, Sakteesh, Sundt, Wendy, Johnson, Stephen , Lennon, Ryan J. , Dyer, Roy B. , Camilleri, Michael , Kashyap, Purna , Farrugia, Gianrico, Grover, Madhusudan , Peters, Stephanie A, Gurunathan, Sakteesh V, Sundt, Wendy J., Johnson, Stephen, Farrugia, Gianrico , Chen, Jun , Singh, Ravinder J.

The FASEB Journal | June 13, 2018 | Volume: 32 | Issue: 12 | Pages: 6615-6625

10.1096/fj.201800560r Get It

ABSTRACT Intestinal barrier function and microbiota are integrally related and play critical roles in maintenance of host physiology. Sex is a key biologic variable for several disorders. Our aim was to determine sex‐based differences in response to perturbation and subsequent recovery of intestinal barrier function and microbiota in healthy humans. Twenty‐three volunteers underwent duodenal biopsies, mucosal impedance, and in vivo permeability measurement. Permeability testing was repeated after administration of indomethacin, then 4 to 6 wk after its discontinuation. Duodenal and fecal microbiota composition was determined using 16S rRNA amplicon sequencing. Healthy women had lower intestinal permeability and higher duodenal and fecal microbial diversity than healthy men. Intestinal permeability increases after indomethacin administration in both sexes. However, only women demonstrated decreased fecal microbial diversity, including an increase in Prevotella abundance, after indomethacin administration. Duodenal microbiota composition did not show sex‐specific changes. The increase in permeability and microbiota changes normalized after discontinuation of indomethacin. In summary, women have lower intestinal permeability and higher microbial diversity. Intestinal permeability is sensitive to perturbation but recovers to baseline. Gut microbiota in women is sensitive to perturbation but appears to be more stable in men. Sex‐based differences in intestinal barrier function and microbiome should be considered in future studies.—Edogawa, S., Peters, S. A., Jenkins, G. D., Gurunathan, S. V., Sundt, W. J., Johnson, S., Lennon, R. J., Dyer, R. B., Camilleri, M., Kashyap, P. C., Farrugia, G., Chen, J., Singh, R. J., Grover, M. Sex differences in NSAID‐induced perturbation of human intestinal barrier function and microbiota. FASEB J. 32, 6615–6625 (2018). www.fasebj.org